Janelle Comita-Prevoir
Overview
Explore the profile of Janelle Comita-Prevoir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Durand-Reville T, Miller A, ODonnell J, Wu X, Sylvester M, Guler S, et al.
Nature
. 2021 Sep;
597(7878):698-702.
PMID: 34526714
The development of new antibiotics to treat infections caused by drug-resistant Gram-negative pathogens is of paramount importance as antibiotic resistance continues to increase worldwide. Here we describe a strategy for...
2.
Furuya T, Shapiro A, Comita-Prevoir J, Kuenstner E, Zhang J, Ribe S, et al.
Bioorg Med Chem
. 2020 Nov;
28(24):115826.
PMID: 33160146
UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase (LpxC), the zinc metalloenzyme catalyzing the first committed step of lipid A biosynthesis in Gram-negative bacteria, has been a target for antibacterial drug discovery for many years. All...
3.
Durand-Reville T, Comita-Prevoir J, Zhang J, Wu X, May-Dracka T, Romero J, et al.
J Med Chem
. 2020 Jul;
63(21):12511-12525.
PMID: 32658473
Multidrug resistant Gram-negative bacterial infections are an increasing public health threat due to rapidly rising resistance toward β-lactam antibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion...
4.
Shapiro A, Comita-Prevoir J, Sylvester M
ACS Infect Dis
. 2019 Mar;
5(6):863-872.
PMID: 30848883
The high-molecular mass penicillin-binding proteins (PBPs) are the essential targets of the β-lactam classes of antibacterial drugs. In the Gram-negative pathogen Escherichia coli, these include PBP1a, PBP1b, PBP2, and PBP3....
5.
Durand-Reville T, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, et al.
Nat Microbiol
. 2017 Jul;
2:17104.
PMID: 28665414
Multidrug-resistant (MDR) bacterial infections are a serious threat to public health. Among the most alarming resistance trends is the rapid rise in the number and diversity of β-lactamases, enzymes that...
6.
Reck F, Ehmann D, Dougherty T, Newman J, Hopkins S, Stone G, et al.
Bioorg Med Chem
. 2014 Aug;
22(19):5392-409.
PMID: 25155913
Type II bacterial topoisomerases are well validated targets for antimicrobial chemotherapy. Novel bacterial type II topoisomerase inhibitors (NBTIs) of these targets are of interest for the development of new antibacterial...
7.
Reck F, Alm R, Brassil P, Newman J, Ciaccio P, McNulty J, et al.
J Med Chem
. 2012 Jul;
55(15):6916-33.
PMID: 22779424
Novel non-fluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the development of new antibacterial agents that are not impacted by target-mediated cross-resistance...
8.
Reck F, Alm R, Brassil P, Newman J, DeJonge B, Eyermann C, et al.
J Med Chem
. 2011 Oct;
54(22):7834-47.
PMID: 21999508
Novel non-fluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the development of new antibacterial agents that are not impacted by target-mediated cross-resistance...
9.
Geng B, Comita-Prevoir J, Eyermann C, Reck F, Fisher S
Bioorg Med Chem Lett
. 2011 Jul;
21(18):5432-5.
PMID: 21782427
An SAR survey at the C-6 benzoxazinone position of a novel scaffold which inhibits bacterial type IIa topoisomerase demonstrates that a range of small electron donating groups (EDG) and electron...
10.
Geng B, Basarab G, Comita-Prevoir J, Gowravaram M, Hill P, Kiely A, et al.
Bioorg Med Chem Lett
. 2008 Dec;
19(3):930-6.
PMID: 19097892
An SAR study of an HTS screening hit generated a series of pyridodiazepine amines as potent inhibitors of Helicobacter pylori glutamate racemase (MurI) showing highly selective anti-H. pylori activity, marked...